The Impact of Comorbidity on Outcomes

Piccirillo, Jay F.; Costas, Irene

doi:10.1159/000079875

Cited by 43 publications

(29 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we did not apply standard comorbidity measures as the Adult Comorbidity Evaluation-27, that are currently used in studies to code and quantify comorbidity. [42][43][44] Nevertheless, we were able to indicate that comorbidity apparently played a larger role in decreased QOL scores than radiotherapy. However, 2 patients received radiotherapy between T 2 and T 3 due to recurrent disease.…”

Section: Discussionmentioning

confidence: 80%

Five‐year follow‐up of oral functioning and quality of life in patients with oral cancer with implant‐retained mandibular overdentures

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 80%

Five‐year follow‐up of oral functioning and quality of life in patients with oral cancer with implant‐retained mandibular overdentures

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Another ecological measure included percent of the population that was in an urban area (100% urban, 100% rural, urban/rural mix). Comorbidities were assessed using the Adult Comorbidity Evaluation (ACE)-27, which includes conditions relevant to cancer treatment choice and outcome, and the severity of these conditions that were present at or before diagnosis [22,23]. Overall comorbidity index (none, low, moderate, or severe) was allotted based on the comorbidity with the highest level of decompensation.…”

Section: Methodsmentioning

confidence: 99%

Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer

Denu

Hampton

Currey

et al. 2016

Cancer Epidemiology

View full text Add to dashboard Cite

Purpose Inflammatory breast cancer (IBC) is an aggressive subtype of breast cancer for which treatments vary, so we sought to identify factors that affect the receipt of guideline-concordant care. Methods Patients diagnosed with IBC in 2004 were identified from the Breast and Prostate Cancer Data Quality and Patterns of Care Study, containing information from cancer registries in seven states. Variation in guideline-concordant care for IBC, based on National Comprehensive Cancer Network (NCCN) guidelines, was assessed according to patient, physician, and hospital characteristics. Results Of the 107 IBC patients in the study without distant metastasis at the time of diagnosis, only 25.8% received treatment concordant with guidelines. Predictors of non-concordance included patient age (≥70 years), non-white race, normal body mass index (BMI 18.5–25 kg/m2), patients with physicians graduating from medical school >15 years prior, and smaller hospital size (<200 beds). IBC patients survived longer if they received guideline-concordant treatment based on either 2003 (p=0.06) or 2013 (p=0.06) NCCN guidelines. Conclusions Targeting factors associated with receipt of care that is not guideline-concordant may reduce survival disparities in IBC patients. Prompt referral for neoadjuvant chemotherapy and postoperative radiation therapy is also crucial.

show abstract

“…Medical records were reviewed for patient demographics, tumor site and stage, treatment, morbidity during and after treatment, and follow-up. Comorbidity was assessed using the Adult Comorbidity Evaluation 27 Index (ACE-27) [12]. …”

Section: Methodsmentioning

confidence: 99%

Chemoradiation for advanced hypopharyngeal carcinoma: a retrospective study on efficacy, morbidity and quality of life

Keereweer

Kerrebijn

Al‐Mamgani

et al. 2011

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Chemoradiation (CRT) is a valuable treatment option for advanced hypopharyngeal squamous cell cancer (HSCC). However, long-term toxicity and quality of life (QOL) is scarcely reported. Therefore, efficacy, acute and long-term toxic effects, and long-term QOL of CRT for advanced HSCC were evaluated,using retrospective study and post-treatment quality of life questionnaires. in a tertiary hospital setting. Analysis was performed of 73 patients that had been treated with CRT. Toxicity was rated using the CTCAE score list. QOL questionnaires EORTC QLQ-C30, QLQ-H&N35, and VHI were analyzed. The most common acute toxic effects were dysphagia and mucositis. Dysphagia and xerostomia remained problematic during long-term follow-up. After 3 years, the disease-specific survival was 41%, local disease control was 71%, and regional disease control was 97%. The results indicated that CRT for advanced HSCC is associated with high locoregional control and disease-specific survival. However, significant acute and long-term toxic effects occur, and organ preservation appears not necessarily equivalent to preservation of function and better QOL.

show abstract

The Impact of Comorbidity on Outcomes

Cited by 43 publications

References 41 publications

Five‐year follow‐up of oral functioning and quality of life in patients with oral cancer with implant‐retained mandibular overdentures

Five‐year follow‐up of oral functioning and quality of life in patients with oral cancer with implant‐retained mandibular overdentures

Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer

Chemoradiation for advanced hypopharyngeal carcinoma: a retrospective study on efficacy, morbidity and quality of life

Contact Info

Product

Resources

About